Table of Content

Table of Content of ICH CTDModule 1: Administrative Information and Prescribing Information (1)Module 2: Common Technical Document Summaries (1)Module 3: Quality (5)Module 4: Nonclinical Study Reports (6)Module 5: Clinical Study Reports (8)Module 1: Administrative Information and Prescribing Information1.1 Table of Contents of the Submission Including Module 11.2 Documents Specific to Each Region (for example, application forms, prescribing information)Module 2: Common Technical Document Summaries2.1 Common Technical Document Table of Contents (Modules 2-5)2.2 CTD Introduction2.3 Quality Overall Summary(QOS)INTRODUCTION2.3.S DRUG SUBSTANCE (NAME, MANUFACTURER)2.3.S.1 General Information (name, manufacturer)2.3.S.2 Manufacture (name, manufacturer)2.3.S.3 Characterisation (name, manufacturer)2.3.S.4 Control of Drug Substance (name, manufacturer)2.3.S.5 Reference Standards or Materials (name, manufacturer)2.3.S.6 Container Closure System (name, manufacturer)2.3.S.7 Stability (name, manufacturer).2.3.P DRUG PRODUCT (NAME, DOSAGE FORM)2.3.P.1 Description and Composition of the Drug Product (name, dosage form)2.3.P.2 Pharmaceutical Development (name, dosage form)2.3.P.3 Manufacture (name, dosage form)2.3.P.4 Control of Excipients (name, dosage form)2.3.P.5 Control of Drug Product (name, dosage form)2.3.P.6 Reference Standards or Materials (name, dosage form)2.3.P.7 Container Closure System (name, dosage form)2.3.P.8 Stability (name, dosage form)2.3.A APPENDICES2.3.A.1 Facilities and Equipment (name, manufacturer)2.3.A.2 Adventitious Agents Safety Evaluation (name, dosage form, manufacturer)2.3.A.3 Excipients2.3.R REGIONAL INFORMATION2.4 Nonclinical Overview2.4.1 Overview of the nonclinical testing strategy2.4.2 Pharmacology2.4.3 Pharmacokinetics2.4.4 Toxicology2.4.5 Integrated overview and conclusions2.4.6 List of literature references2.5 Clinical Overview2.5.1 Product Development Rationale2.5.2 Overview of Biopharmaceutics2.5.3 Overview of Clinical Pharmacology2.5.4 Overview of Efficacy2.5.5 Overview of Safety2.5.6 Benefits and Risks Conclusions2.5.7 Literature References2.6 Nonclinical Written and Tabulated Summaries PharmacologyPharmacokineticsToxicology2.6.1 Introduction2.6.2 Pharmacology Written Summary2.6.2.1 Brief Summary2.6.2.2 Primary Pharmacodynamics2.6.2.3 Secondary Pharmacodynamics2.6.2.4 Safety Pharmacology2.6.2.5 Pharmacodynamic Drug Interactions2.6.2.6 Discussion and Conclusions2.6.2.7 Tables and Figures2.6.3 Pharmacology Tabulated Summary (see Appendix B)2.6.3.1 Pharmacology: Overview2.6.3.2 Primary Pharmacodynamics*2.6.3.3 Secondary Pharmacodynamics*2.6.3.4 Safety Pharmacology2.6.3.5 Pharmacodynamic Drug Interactions*2.6.4 Pharmacokinetics Written Summary2.6.4.1 Brief Summary2.6.4.2 Methods of Analysis2.6.4.3 Absorption2.6.4.4 Distribution2.6.4.5 Metabolism (interspecies comparison)2.6.4.6 Excretion2.6.4.7 Pharmacokinetic Drug Interactions2.6.4.8 Other Pharmacokinetic Studies2.6.4.9 Discussion and Conclusions2.6.4.10 Tables and Figures2.6.5 Pharmacokinetics Tabulated Summary (see Appendix B)2.6.5.1 Pharmacokinetics: Overview2.6.5.2 Analytical Methods and Validation Reports*2.6.5.3 Pharmacokinetics: Absorption after a Single Dose2.6.5.4 Pharmacokinetics: Absorption after Repeated Doses2.6.5.5 Pharmacokinetics: Organ Distribution2.6.5.6 Pharmacokinetics: Plasma Protein Binding2.6.5.7 Pharmacokinetics: Study in Pregnant or Nursing Animals2.6.5.8 Pharmacokinetics: Other Distribution Study2.6.5.9 Pharmacokinetics: Metabolism In Vivo2.6.5.10 Pharmacokinetics: Metabolism In Vitro2.6.5.11 Pharmacokinetics: Possible Metabolic Pathways2.6.5.12 Pharmacokinetics: Induction/Inhibition of Drug-Metabolizing Enzymes2.6.5.13 Pharmacokinetics: Excretion2.6.5.14 Pharmacokinetics: Excretion into Bile2.6.5.15 Pharmacokinetics: Drug-Drug Interactions2.6.5.16 Pharmacokinetics: Other2.6.6 Toxicology Written Summary2.6.6.1 Brief Summary2.6.6.2 Single-Dose Toxicity2.6.6.3 Repeat-Dose Toxicity (including supportive toxicokinetics evaluation)2.6.6.4 Genotoxicity2.6.6.5 Carcinogenicity (including supportive toxicokinetics evaluations)2.6.6.6 Reproductive and Developmental Toxicity (including range-finding studies and supportive toxicokinetics evaluations)2.6.6.7 Local Tolerance2.6.6.8 Other Toxicity Studies (if available)2.6.6.9 Discussion and Conclusions2.6.6.10 Tables and Figures2.6.7 Toxicology Tabulated Summary (see Appendix B)2.6.7.1 Toxicology: Overview2.6.7.2 Toxicokinetics: Overview of Toxicokinetics Studies2.6.7.3 Toxicokinetics: Overview of Toxicokinetics Data2.6.7.4 Toxicology: Drug Substance2.6.7.5 Single-Dose Toxicity2.6.7.6 Repeat-Dose Toxicity: Non-Pivotal Studies2.6.7.7 Repeat-Dose Toxicity: Pivotal Studies2.6.7.8 Genotoxicity: In Vitro2.6.7.9 Genotoxicity: In Vivo2.6.7.10 Carcinogenicity2.6.7.11 Reproductive and Developmental Toxicity: Non-Pivotal Studies2.6.7.12 Reproductive and Developmental Toxicity –Fertility and Early Embryonic Development to Implantation (Pivotal)2.6.7.13 Reproductive and Developmental Toxicity –Effects on Embryo-Fetal Development (Pivotal)2.6.7.14 Reproductive and Developmental Toxicity –Effects on Pre- and Postnatal Development, Including Maternal Function (Pivotal)2.6.7.15 Studies in Juvenile Animalsa2.6.7.16 Local Tolerance2.6.7.17 Other Toxicity Studies2.7 Clinical Summary2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods2.7.1.1 Background and Overview2.7.1.2 Summary of Results of Individual Studies2.7.1.3 Comparison and Analyses of Results Across Studies2.7.1.4 Appendix2.7.2 Summary of Clinical Pharmacology Studies2.7.2.1 Background and Overview2.7.2.2 Summary of Results of Individual Studies2.7.2.3 Comparison and Analyses of Results Across Studies2.7.2.4 Special Studies2.7.2.5 Appendix2.7.3 Summary of Clinical Efficacy2.7.3.1 Background and Overview of Clinical Efficacy2.7.3.2 Summary of Results of Individual Studies2.7.3.3 Comparison and Analyses of Results Across Studies2.7.3.3.1 Study Populations2.7.3.3.2 Comparison of Efficacy Results of all Studies2.7.3.3.3 Comparison of Results in Sub-populations2.7.3.4 Analysis of Clinical Information Relevant to Dosing Recommendations2.7.3.5 Persistence of Efficacy and/or Tolerance Effects2.7.3.6 Appendix2.7.4 Summary of Clinical Safety2.7.4.1 Exposure to the Drug2.7.4.1.1 Overall Safety Evaluation Plan and Narratives of Safety Studies2.7.4.1.2 Overall Extent of Exposure2.7.4.1.3 Demographic and Other Characteristics of Study Population2.7.4.2 Adverse Events2.7.4.2.1 Analysis of Adverse Events2.7.4.2.2 Narratives2.7.4.3 Clinical Laboratory Evaluations2.7.4.4 Vital Signs, Physical Findings, and Other Observations Related to Safety2.7.4.5 Safety in Special Groups and Situations2.7.4.5.1 Intrinsic Factors2.7.4.5.2 Extrinsic Factors2.7.4.5.3 Drug Interactions2.7.4.5.4 Use in Pregnancy and Lactation2.7.4.5.5 Overdose2.7.4.5.6 Drug Abuse2.7.4.5.7 Withdrawal and Rebound2.7.4.5.8 Effects on Ability to Drive or Operate Machinery or Impairment of MentalAbility2.7.4.6 Post-marketing Data2.7.4.7 Appendix2.7.5 Literature References2.7.6 Synopses of Individual StudiesModule 3: Quality3.1 Table of Contents of Module 33.2 Body of Data(数据汇总)3.2.S DRUG SUBSTANCE (NAME, MANUFACTURER)3.2.S.1 General Information (name, manufacturer)3.2.S.1.1 Nomenclature (name, manufacturer)3.2.S.1.2 Structure (name, manufacturer)3.2.S.1.3 General Properties (name, manufacturer)3.2.S.2 Manufacture (name, manufacturer)3.2.S.2.1 Manufacturer(s) (name, manufacturer)3.2.S.2.2 Description of Manufacturing Process and Process Controls (name, manufacturer)3.2.S.2.3 Control of Materials (name, manufacturer)3.2.S.2.4 Controls of Critical Steps and Intermediates (name, manufacturer)3.2.S.2.5 Process Validation and/or Evaluation (name, manufacturer)3.2.S.2.6 Manufacturing Process Development (name, manufacturer)3.2.S.3 Characterisation (name, manufacturer)3.2.S.3.1 Elucidation of Structure and other Characteristics (name, manufacturer)3.2.S.3.2 Impurities (name, manufacturer)3.2.S.4 Control of Drug Substance (name, manufacturer)3.2.S.4.1 Specification (name, manufacturer)3.2.S.4.2 Analytical Procedures (name, manufacturer)3.2.S.4.3 Validation of Analytical Procedures (name, manufacturer)3.2.S.4.4 Batch Analyses (name, manufacturer)3.2.S.4.5 Justification of Specification (name, manufacturer)3.2.S.5 Reference Standards or Materials (name, manufacturer)3.2.S.6 Container Closure System (name, manufacturer)3.2.S.7 Stability (name, manufacturer)3.2.S.7.1 Stability Summary and Conclusions (name, manufacturer)3.2.S.7.2 Post-approval Stability Protocol and Stability Commitment (name, manufacturer)3.2.S.7.3 Stability Data (name, manufacturer)3.2.P DRUG PRODUCT (NAME, DOSAGE FORM)3.2.P.1 Description and Composition of the Drug Product (name, dosage form)3.2.P.2 Pharmaceutical Development (name, dosage form)3.2.P.2.1 Components of the Drug Product (name, dosage form)3.2.P.2.1.1 Drug Substance (name, dosage form)3.2.P.2.1.2 Excipients (name, dosage form)3.2.P.2.2 Drug Product (name, dosage form)3.2.P.2.2.1 Formulation Development (name, dosage form)3.2.P.2.2.2 Overages (name, dosage form)3.2.P.2.2.3 Physicochemical and Biological Properties (name, dosage form)3.2.P.2.3 Manufacturing Process Development (name, dosage form)3.2.P.2.4 Container Closure System (name, dosage form)3.2.P.2.5 Microbiological Attributes (name, dosage form)3.2.P.2.6 Compatibility (name, dosage form)3.2.P.3 Manufacture (name, dosage form)3.2.P.3.1 Manufacturer(s) (name, dosage form)3.2.P.3.2 Batch Formula (name, dosage form)3.2.P.3.3 Description of Manufacturing Process and Process Controls (name, dosage form)3.2.P.3.4 Controls of Critical Steps and Intermediates (name, dosage form)3.2.P.3.5 Process Validation and/or Evaluation (name, dosage form)3.2.P.4 Control of Excipients (name, dosage form)3.2.P.4.1 Specifications (name, dosage form)3.2.P.4.2 Analytical Procedures (name, dosage form)3.2.P.4.3 Validation of Analytical Procedures (name, dosage form)3.2.P.4.4 Justification of Specifications (name, dosage form)3.2.P.4.5 Excipients of Human or Animal Origin (name, dosage form)3.2.P.4.6 Novel Excipients (name, dosage form)3.2.P.5 Control of Drug Product (name, dosage form)3.2.P.5.1 Specification(s) (name, dosage form)3.2.P.5.2 Analytical Procedures (name, dosage form)3.2.P.5.3 Validation of Analytical Procedures (name, dosage form)3.2.P.5.4 Batch Analyses (name, dosage form)3.2.P.5.5 Characterisation of Impurities (name, dosage form)3.2.P.5.6 Justification of Specification(s) (name, dosage form)3.2.P.6 Reference Standards or Materials (name, dosage form)3.2.P.7 Container Closure System (name, dosage form)3.2.P.8 Stability (name, dosage form)3.2.P.8.1 Stability Summary and Conclusion (name, dosage form)3.2.P.8.2 Post-approval Stability Protocol and Stability Commitment (name, dosage form)3.2.P.8.3 Stability Data (name, dosage form)3.2.A APPENDICES3.2.A.1 Facilities and Equipment (name, manufacturer)3.2.A.2 Adventitious Agents Safety Evaluation (name, dosage form, manufacturer)3.2.A.3 Excipients3.2.R REGIONAL INFORMATION3.3 Literature ReferencesModule 4: Nonclinical Study Reports4.1 Table of Contents of Module 44.2 Study Reports(见正文)4.2.1 Pharmacology4.2.1.1 Primary Pharmacodynamics4.2.1.2 Secondary Pharmacodynamics4.2.1.3 Safety Pharmacology4.2.1.4 Pharmacodynamic Drug Interactions4.2.2 Pharmacokinetics4.2.2.1 Analytical Methods and Validation Reports (if separate reports are available)4.2.2.2 Absorption4.2.2.3 Distribution4.2.2.4 Metabolism4 2.2.5 Excretion4.2.2.6 Pharmacokinetic Drug Interactions (nonclinical)4.2.2.7 Other Pharmacokinetic Studies4.2.3 Toxicology4.2.3.1 Single-Dose Toxicity (in order by species, by route)4.2.3.2 Repeat-Dose Toxicity (in order by species, by route, by duration; including supportive toxicokinetics evaluations)4.2.3.3 Genotoxicity4.2.3.3.1 In vitro4.2.3.3.2 In vivo (including supportive toxicokinetics evaluations)4.2.3.4 Carcinogenicity (including supportive toxicokinetics evaluations)4.2.3.4.1 Long-term studies (in order by species; including range-finding studies that cannot appropriately be included under repeat-dose toxicity or pharmacokinetics)4.2.3.4.2 Short- or medium-term studies (including range-finding studies that cannot appropriately be included under repeat-dose toxicity or pharmacokinetics)4.2.3.4.3 Other studies4.2.3.5 Reproductive and Developmental Toxicity (including range-finding studies and supportive toxicokinetics evaluations) (If modified study designs are used, the following sub-headings should be modified accordingly.)4.2.3.5.1 Fertility and early embryonic development4.2.3.5.2 Embryo-fetal development4.2.3.5.3 Prenatal and postnatal development, including maternal function4.2.3.5.4 Studies in which the offspring (juvenile animals) are dosed and/or further evaluated.4.2.3.6 Local Tolerance4.2.3.7 Other Toxicity Studies (if available)4.2.3.7.1 Antigenicity4.2.3.7.2 Immunotoxicity4.2.3.7.3 Mechanistic studies (if not included elsewhere)4.2.3.7.4 Dependence4.2.3.7.5 Metabolites4.2.3.7.6 Impurities4.2.3.7.7 Other4.3 Literature ReferencesModule 5: Clinical Study Reports5.1 Table of Contents of Module 55.2 Tabular Listing of All Clinical Studies5.3 Clinical Study Reports5.3.1 Reports of Biopharmaceutic Studies5.3.1.1 Bioavailability (BA) Study Reports5.3.1.2 Comparative BA and Bioequivalence (BE) Study Reports5.3.1.3 In Vitro – In Vivo Correlation Study Reports5.3.1.4 Reports of Bioanalytical and Analytical Methods for Human Studies5.3.2 Reports of Studies Pertinent to Pharmacokinetics Using Human Biomaterials5.3.2.1 Plasma Protein Binding Study Reports5.3.2.2 Reports of Hepatic Metabolism and Drug Interaction Studies5.3.2.3 Reports of Studies Using Other Human Biomaterials5.3.3 Reports of Human Pharmacokinetic (PK) Studies5.3.3.1 Healthy Subject PK and Initial Tolerability Study Reports5.3.3.2 Patient PK and Initial Tolerability Study Reports5.3.3.3 Intrinsic Factor PK Study Reports5.3.3.4 Extrinsic Factor PK Study Reports5.3.3.5 Population PK Study Reports5.3.4 Reports of Human Pharmacodynamic (PD) Studies5.3.4.1 Healthy Subject PD and PK/PD Study Reports5.3.4.2 Patient PD and PK/PD Study Reports5.3.5 Reports of Efficacy and Safety Studies5.3.5.1 Study Reports of Controlled Clinical Studies Pertinent to the Claimed Indication5.3.5.2 Study Reports of Uncontrolled Clinical Studies5.3.5.3 Reports of Analyses of Data from More than One Study5.3.5.4 Other Study Reports5.3.6 Reports of Post-Marketing Experience5.3.7 Case Report Forms and Individual Patient Listings5.4 Literature ReferencesANNEX : Granularity Document参考ICH guidelines：M4E R1M4Q R1M4S R2。

Table of Contents（加粗，小二号，居中）
（中间空一行，使用段落中的空行标准）
Acknowledgements（加粗，四号） (i)
（此处空一行，使用段落中的空行标准）
Abstract (加粗，四号) (ii)
摘要(宋体，四号、加粗) (iii)
（此处空一行，使用段落中的空行标准）
Introduction(宋体，加粗，四号) (1)
I. Nature of Translation (加粗，四号，I. 点后空一格) (2)
1.1 Translation Is a Science (小四，不加粗，缩进) (2)
1.2 Translation Is an Art (同上) (4)
II. Prose Cognition （加粗，四号） (10)
2.1 What Is Prose?(小四，不加粗，缩进) (10)
2.2 What Are the Characteristics of Prose? (小四，不加粗) (10)
III. Aesthetics & Translation (11)
Conclusion（加粗，四号） (20)
Bibliography（加粗，四号） (21)
（此页英文字体Times New Roman，汉语宋体；页边距上、左2.5；下、右2.0；除Table of Contents为居中外其余行均为分散对齐；题号点后与题目之间空一格；次级题号与上一行词首对齐；此页不需页码）
段落中的空行标准操作方法：选中文本，点击菜单中的“段落”，选择“段前”空一行或“段后”空一行。

这样做出的空行大小适度，美观工整。

SCI的table of content entry指的是期刊目录的条目，通过它读者可以了解文章的基本内容和结构，从而决定是否需要深入阅读全文。

在很多知名的自然科学期刊中，期刊目录不再是简单题目的罗列，而是由题目、作者和图文摘要组成。

如果出版社编辑向作者询问Table of Content（TOC）的问题，一般指的就是图文摘要部分。

在写Table of Content entry 时，有以下几点注意事项：
1. 准确性：确保Table of Content entry 中的信息准确无误，包括文章标题、作者姓名、页码等。

2. 简洁明了：Table of Content entry 应该简洁明了，能够准确地传达文章的核心内容，同时避免过于冗长。

3. 一致性：保持Table of Content entry 的格式和风格一致，以增强整个文档的可读性。

4. 层次结构：如果文档有多个层级的标题，确保Table of Content entry 反映出正确的层次结构。

5. 完整性：确保所有的章节、部分和子部分都在Table of Content entry 中列出，以方便读者快速找到所需内容。

6. 更新及时：在文档内容发生变化时，及时更新Table of Content entry，以确保其与文档的实际内容保持一致。

遵循以上注意事项，可以帮助你写出清晰、准确、易于阅读的Table of Content entry，提高文档的整体质量。

Supplemental Digital Content1. Methods to evaluate hepatic steatosisMRI is known to be the most accurate noninvasive method available to assess hepatic steatosis. Since only a portion of the patients in our study cohort underwent liver MRI, assessment of hepatic steatosis using MRI was only possible in these patients. Although it is less straightforward than the use of MRI or unenhanced CT, several studies1-3 have shown that hepatic steatosis can be evaluated using contrast-enhanced liver CT with moderate accuracy. The contrast-enhanced CT method had an advantage that it could be consistently applied to all patients of our study. One major limitation with contrast-enhanced CT, however, is the lack of truly generalized criteria to diagnose hepatic steatosis on contrast-enhanced CT, largely related to the variability caused by differences in contrast-enhancement methods. Therefore, we evaluated hepatic steatosis using contrast-enhanced CT for the entire study cohort and, in addition, using both MRI and contrast-enhanced CT in the patients who had undergone liver MRI. Given the limited accuracy of the contrast-enhanced CT method, we then estimated the prevalence of hepatic steatosis for the entire study cohort by referring to the comparative results of MRI and CT obtained in the subset of patients who had undergone MRI.The contrast-enhanced CT assessment of hepatic steatosis was according to quantitative attenuation measurement (in Hounsfield unit [HU]) of the liver and spleen using a standard region of interest (ROI) technique at a commercial picture archiving and communication system workstation (PetaVision; Asan Medical Center, Seoul, Korea). Mean liver and spleen attenuation was obtained by averaging three 1-cm2 square ROIs placed in each organ. The ROIs were placed in the central portion of the right hepatic lobe approximately at the level of hepatic hilum and in the central portion of the spleen at a similar level. Special care was taken to measure representative areas of hepatic and splenic parenchyma and to avoid any focal lesions or visible vessels. The ROI measurement was performed for all but two patients (861 patients). Two patients could not be evaluated due to the presence of numerous hepatic cysts and/or hamartomas and history of splenectomy. Hepatic steatosis was diagnosed on contrast-enhanced CT if the mean hepatic attenuation was lower than the mean splenic attenuation by greater than 20 HU.1, 2The MRI assessment of hepatic steatosis used a well-established dual-echo T1-weighted imaging method which compares hepatic signal intensity between in-phase and opposed-phase T1-weighted MR images. Hepatic signal intensity was measured using a standard ROI technique at a commercial picture archiving and communication system workstation (PetaVision; Asan Medical Center, Seoul, Korea). Three 1-cm2 square ROIs were placed in the central portion of the right hepatic lobe approximately at the level of hepatic hilum, with a particular care to measure representative areas and to avoid any focal lesions or visible vessels. The ROIs on the in-phase images were copied on to the opposed-phase images so that the corresponding ROIs were placed in the same location. Hepatic fat fraction was derived from the ROI measurements using the following equation: fat fraction = (S in- S ou t) ÷2S in⨯ 100 (%), where S in is the signal intensity on the in-phase image and S out is the signalintensity on the opposed-phage image. Hepatic steatosis was then diagnosed on MRI when the average hepatic fat fraction value of the three ROI locations was greater than 1.5%.4 2. Scan parameters for diffusion-weighted imaging of the liverDiffusion-weighted images were acquired using a respiratory-triggered, single-shot echo planar sequence with diffusion-weighted gradients (i.e., b-factors) of 0, 50, and 900 s/mm2 applied in three orthogonal directions. The other scan parameters for diffusion-weighted imaging were as follows: TR of approximately 3000-5000 ms; TE of 81 ms; slice section thickness of 6 mm; interslice gap of 1.2 mm; matrix of 192×162; number of signal averages of 5; use of parallel imaging technique with an acceleration factor of 2; fat saturation using the chemical shift-selective fat suppression technique; and rectangular field of view to fit.3. Patients whose benign focal hepatic lesions were determined by lesion resolutionCasenumber Age GenderPost-resolutionfollow-up length Additional imaging features1 F 55 29 months Size: <1 cmMRI: typical findings of a benign lesion*18F-FDG PET/CT: negative2 M 61 18 months Size: <1 cmMRI: typical findings of a benign lesion*18F-FDG PET/CT: negative3 F 67 12 months Size: <1 cmMRI: typical findings of a benign lesion*18F-FDG PET/CT: negative4 F 44 23 months Size: approximately 1.5 cmMRI: ill-define patchy abnormal parenchymal signalto suggest an inflammatory lesion5 M 65 23 months Size: approximately 1.3 cmMRI: ill-define patchy abnormal parenchymal signalto suggest an inflammatory lesion18F-FDG PET/CT: negative.6 M 56 29 months Size: approximately 1.2 cmMRI: ill-define patchy abnormal parenchymal signalto suggest an inflammatory lesion*Bright high signal on T2-weighted imaging, lack of enhancement on contrast-enhanced T1-weighted imaging, and lack of diffusion restriction.4. TSTC-liver-on-CT and negative-liver-on-CT patients who did not have adequate follow-upTSTC-liver-on-CT (n=31)‡Negative-liver-on-CT (n=24)‡Mean age (SD) 65.8 years (11.0) 67.5 years (12.6)GenderFemale 12 (39) 9 (38)Male 19 (61) 15 (63) Tumor locationColon20 (65) 7 (29) Rectum 11 (35) 17 (71) AJCC stage at presentation*Stage 0 3 (10) 3 (13) Stage 1 5 (16) 5 (21) Stage 2 5 (16) 4 (17) Stage 3 14 (45) 12 (50) Stage 4 4 (13) 0 (0)Serum CEA (ng/mL), median (range)†(n=28)2.4 (0.51-398)(n=19) 2.3 (0.48-148)Data are shown as the number of patients with percentages in parentheses (sum of which may not be 100% due to rounding), unless otherwise specified. When synchronous cancers were present, data are presented according to the most-advanced lesion.*According to AJCC 7th edition and excluding hepatic metastasis. Staging was classified according to pathologic TNM whenever applicable. In those patients treated nonsurgically, clinical staging information was used when pathologic staging data were lacking. The T and N stages of the rectal cancers that were treated using preoperative chemoradiation were determined at the pretreatment rectal MRI.†Number of patients with serum CEA data is provided in the parentheses.‡Reasons for the lack of adequate follow-up included transfer to another hospital or loss on follow-up (n=25), lack of imaging follow-up in patients who underwent curative endoscopic resection of early cancer (n=3), non-cancer-related death (n=2), or unspecified reasons (n=1) in TSTC-liver-on-CT group and were transfer to another hospital or loss on follow-up (n=17), curative endoscopic resection of early cancer (n=6), or unspecified reasons (n=1) in negative-liver-on-CT group.5. Patients with hepatic metastases that manifested as TSTC lesionsCase numberAge(years) Gender Tumor locationAJCC stage at presentation*Serum CEA(ng/mL)T N M Overall1 56 M Rectum 3 1 0 3B 1.22 54 M Rectum3 1 0 3B 1.73 61 F Rectum4 2 1 4B 534 79 F Ascending colon 3 1 0 3B 1.15 68 M Rectum 3 1 0 3B 3.0*According to AJCC 7th edition and excluding hepatic metastasis. Staging was classified according to pathologic TNM whenever applicable. In those patients treated nonsurgically, clinical staging information was used when pathologic staging data were lacking. The T and N stages of the rectal cancers that were treated using preoperative chemoradiation were determined at the pretreatment rectal MRI.6. References for Supplemental Digital Content1) Kim DY, Park SH, Lee SS, et al. Contrast-enhanced computed tomography for thediagnosis of fatty liver: prospective study with same-day biopsy used as the referencestandard. Eur Radiol. 2010;20:359-366.2) Jacobs JE, Birnbaum BA, Shapiro MA, et al. Diagnostic criteria for fatty infiltrationof the liver on contrast-enhanced helical CT. AJR Am J Roentgenol. 1998;171:659-664.3) Lawrence DA, Oliva IB, Israel GM. Detection of hepatic steatosis on contrast-enhanced CT images: diagnostic accuracy of identification of areas of presumed focal fatty sparing. AJR Am J Roentgenol. 2012;199:44-47.4) van Werven JR, Marsman HA, Nederveen AJ, et al. Assessment of hepatic steatosis inpatients undergoing liver resection: comparison of US, CT, T1-weighted dual-echoMR imaging, and point-resolved 1H MR spectroscopy. Radiology. 2010;256:159-168.。

Software RequirementsSpecificationfor<Project>软件需求规格说明Version 1.0 approvedPrepared by <author><organization><date created>Translated by Hiphonejohn Contact Me , E-mail:hiphonejohn@Table of Contents目录Table of Contents目录 (iii)Revision History版本历史 (iii)1.Introduction 引言 (1)1.1Purpose 目的 (1)1.2Document Conventions 文档约定 (1)1.3Intended Audience and Reading Suggestions使用人群和阅读建议 (1)1.4Product Scope 产品范围 (1)1.5References参考文献 (1)2.Overall Description 总体描述 (2)2.1Product Perspective产品愿景 (2)2.2Product Functions产品功能 (2)2.3User Classes and Characteristics用户类型和特征 (2)2.4Operating Environment操作环境 (3)2.5Design and Implementation Constraints设计和实现约束 (3)2.6User Documentation用户文档 (3)2.7Assumptions and Dependencies假设和依赖 (3)3.External Interface Requirements外部接口需求 (4)3.1User Interfaces用户接口 (4)3.2Hardware Interfaces硬件接口 (4)3.3Software Interfaces软件接口 (4)3.4Communications Interfaces通信接口 (4)4.System Features系统特征 (5)4.1System Feature 1系统特征1 (5)4.2System Feature 2 (and so on)系统特征2，如上。

Operating ManualAgilent TechnologiesElectronic Load MainframesModels 6050A and 6051AFor instruments with Serial Numbers:Agilent 6050A-2908A-00101 and AboveAgilent 6051A-2927A-00101 and AboveAgilent Part No. 5959-3368 Printed in USA: October, 1997 Microfiche Part No. 5959-3369 Reprinted April, 2000CERTIFICATIONAgilent Technologies certifies that this product met its published specifications at time of shipment from the factory. Agilent Technologies further certifies that its calibration measurements are traceable to the United States National Bureau of Standards, to the extent allowed by the Bureau’s calibration facility, and to the calibration facilities of other International Standards Organization members.WARRANTYThis Agilent Technologies hardware product is warranted against defects in material and workmanship for a period of three years from date of delivery. Agilent Technologies software and firmware products, which are designated by Agilent Technologies for use with a hardware product and when properly installed on that hardware product, are warranted not to fail to execute their programming instructions due to defects in material and workmanship for a period of 90 days from date of delivery. During the warranty period Agilent Technologies will, at its option, either repair or replace products which prove to be defective. Agilent Technologies does not warrant that the operation of the software, firmware, or hardware shall be uninterrupted or error free.For warranty service, with the exception of warranty options, this product must be returned to a service facility designated by Agilent Technologies Customer shall prepay shipping charges by (and shall pay all duty and taxes) for products returned to Agilent Technologies for warranty service. Except for products returned to Customer from another country, Agilent Technologies shall pay for return of products to Customer.Warranty services outside the country of initial purchase are included in Agilent Technologies product price, only if Customer pays Agilent Technologies international prices (defined as destination local currency price, or U.S. or Geneva Export price).If Agilent Technologies is unable, within a reasonable time to repair or replace any product to condition as warranted, the Customer shall be entitled to a refund of the purchase price upon return of the product to Agilent TechnologiesLIMITATION OF WARRANTYThe foregoing warranty shall not apply to defects resulting from improper or inadequate maintenance by the Customer, Customer-supplied software or interfacing, unauthorized modification or misuse, operation outside of the environmental specifications for the product, or improper site preparation and maintenance. NO OTHER WARRANTY IS EXPRESSED OR IMPLIED. AGILENT TECHNOLOGIES SPECIFICALLY DISCLAIMS THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.EXCLUSIVE REMEDIESTHE REMEDIES PROVIDED HEREIN ARE THE CUSTOMER’S SOLE AND EXCLUSIVE REMEDIES. AGILENT TECHNOLOGIES SHALL NOT BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, INCIDENTAL, OR CONSEQUENTIAL DAMAGES, WHETHER BASED ON CONTRACT, TORT, OR ANY OTHER LEGAL THEORY.ASSISTANCEThe above statements apply only to the standard product warranty. Warranty options, extended support contracts, product maintenance agreements and customer assistance agreements are also available. Contact your nearest Agilent Technologies Sales and Service office for further information on Agilent Technologies’ full line of Support Programs.23SAFETY SUMMARYThe following general safety precautions must be observed during all phases of operation, service, and repair of this instrument. Failure to comply with these precautions or with specific warnings elsewhere in this manual violates safety standards of design, manufacture, and intended use of the instrument. Agilent Technologies assumes no liability for the customer’s failure to comply with these requirements.BEFORE APPLYING POWER.Verify that the product is set to match the available line voltage and the correct fuse is installed.GROUND THE INSTRUMENT.This product is a Safety Class 1 instrument (provided with a protective earth terminal). To minimize shock hazard, the instrument chassis and cabinet must be connected to an electrical ground. The instrument must be connected to the ac power supply mains through a three-conductor power cable, with the third wire firmly connected to an electrical ground (safety ground) at the power outlet. For instruments designed to be hard-wired to the ac power lines (supply mains), connect the protective earth terminal to a protective conductor before any other connection is made. Any interruption of the protective (grounding) conductor or disconnection of the protective earth terminal will cause a potential shock hazard that could result in personal injury. If the instrument is to be energized via an external autotransformer for voltage reduction, be certain that the autotransformer common terminal is connected to the neutral (earthed pole) of the ac power lines (supply mains).FUSES.Only fuses with the required rated current, voltage, and specified type (normal blow, time delay, etc.) should be used. Do not use repaired fuses or short circuited fuseholders. To do so could cause a shock or fire hazard.DO NOT OPERATE IN AN EXPLOSIVE ATMOSPHERE.Do not operate the instrument in the presence of flammable gases or fumes.KEEP AWAY FROM LIVE CIRCUITS.Operating personnel must not remove instrument covers. Component replacement and internal adjustments must be made by qualified service personnel. Do not replace components with power cable connected. Under certain conditions, dangerous voltages may exist even with the power cable removed. To avoid injuries, always disconnect power, discharge circuits and remove external voltage sources before touching components.DO NOT SERVICE OR ADJUST ALONE.Do not attempt internal service or adjustment unless another person, capable of rendering first aid and resuscitation, is present.DO NOT EXCEED INPUT RATINGS.This instrument may be equipped with a line filter to reduce electromagnetic interference and must be connected to a properly grounded receptacle to minimize electric shock hazard. Operation at line voltages or frequencies in excess of those stated on the data plate may cause leakage currents in excess of 5.0 mA peak.SAFETY SYMBOLS.Instruction manual symbol: the product will be marked with this symbol when it is necessary for the user to refer to theinstruction manual (refer to Table of Contents) .Indicates hazardous voltages.Indicate earth (ground) terminal.The WARNING sign denotes a hazard. It calls attention to a procedure, practice, or the like, which, if not correctlyperformed or adhered to, could result in personal injury. Do not proceed beyond a WARNING sign until theindicated conditions are fully understood and met.The CAUTION sign denotes a hazard. It calls attention to an operating procedure, or the like, which, if not correctlyperformed or adhered to, could result in damage to or destruction of part or all of the product. Do not proceedbeyond a CAUTION sign until the indicated conditions are fully understood and met.DO NOT SUBSTITUTE PARTS OR MODIFY INSTRUMENT.Because of the danger of introducing additional hazards, do not install substitute parts or perform any unauthorized modification to the instrument. Return the instrument to an Agilent Technologies Sales and Service Office for service and repair to ensure that safety features are maintained.Instruments which appear damaged or defective should be made inoperative and secured against unintended operation until they can berepaired by qualified service personnel.4SAFETY SUMMARY (continued)GENERALAny LEDs used in this product are Class 1 LEDs as per IEC 825-l.ENVIRONMENTAL CONDITIONSThis instruments is intended for indoor use in an installation category II, pollution degree 2 environment. It is designed to operate at a maximum relative humidity of 95% and at altitudes of up to 2000 meters. Refer to the specifications tables for the ac mains voltage requirements and ambient operating temperature range.SAFETY SYMBOL DEFINITIONSSymbol Description Symbol DescriptionAlternating currentBoth direct and alternating currentThree-phase alternating currentEarth (ground) terminalProtective earth (ground) terminalFrame or chassis terminalDECLARATION OF CONFORMITYaccording to ISO/IEC Guide 22 and EN 45014Manufacturer’s Name: Agilent Technologies, Inc.Manufacturer’s Address: New Jersey Division150 Green Pond RoadRockaway, NJ 07866 U.S.A.declares that the productProduct Name:Load mainframe and modulesModel Number(s):Agilent 6050A, 6051A mainframes with modulesAgilent 60501A/B, 60502A/B, 60503A/B, 60504A/B, 60507A/Bconform(s) to the following Product Specifications:Safety:IEC 348:1978 / HD401 S1:19811EMC:CISPR 11:1990 / EN 55011:1991 Group 1, Class BIEC 801-2:1991 / EN 50082-1:19924kV CD, 8 kV ADIEC 801-3:1984 / EN 50082-1:1992 3 V/mIEC 801-4:1988 / EN 50082-1:19920.5 kV Sig. Lines, 1 kV Power Lines Supplementary Information:The product herewith complies with the requirements of the Low Voltage Directive 73/23/EEC and the EMC Directive 89/336/EEC and carries the CE-marking accordingly.Note 1: The product family was introduced prior to 12/93--------------------------------------------------------New Jersey, January 1997Bruce Krueger / Quality Manager European Contact: Your local Agilent Technologies Sales and Service Office or Agilent Technologies GmbH,Department TRE, Herrenberger Strasse 130, D-71034 Boeblingen (FAX:+49-7031-14-3143)Printing HistoryThe current edition of this guide is indicated below. Reprints of this guide containing minor corrections and updates may have the same printing date. New editions are identified by a new printing date and, in some cases, by a new part number.A new edition incorporates all new or corrected material since the previous edition. Changes to the guide occurring between editions are covered by change sheets shipped with the guide. Also, if the serial number prefix of your power module is higher than those listed on the title page of this guide, then it may or may not include a change sheet. That is because even though the higher serial prefix indicates a design change, that change may not affect the content of the guide. Edition 3May, 1993© Copyright 1993 Agilent Technologies, Inc. .....................October, 1997Update.........April, 2000This document contains proprietary information protected by copyright. All rights are reserved. No part of this document may be photocopied, reproduced, or translated into another language without the prior consent of Agilent Technologies The information contained in this document is subject to change without notice.56If you are a first-time user, start with this manual, paying particular attention to Chapter 2. After installation (Chapter 3),read Chapter 4 to learn front-panel operation. Programming users should then read Chapter 5 before going to theProgramming Reference Guide. Experienced programming users will probably refer only to the Programming Reference Guide.Agilent 6050A/6051A Operating ManualAgilent Part No. 5959-3368(this manual)SpecificationsSystem OverviewInstallation ProceduresFront-Panel Operation RemoteProgramming IntroductionCalibration ProceduresModule-Specific PagesAgilent Models 60501A/B, 60502A/B, 60503A/B,60504A/B, 60507BSpecificationsProgramming RangesFactory Default SettingsCalibration InformationAgilent Technologies Electronic Load FamilyProgramming Reference GuideAgilent Part No. 06060-90005Introduction to HPSLIntroduction to ProgrammingLanguage DictionaryStatus ReportingAgilent 6050A/605L4 Service ManualModule Service Manuals* Supplied with Agilent 6050A/6051A Electronic Load Mainframe.** Supplied with individual load modules.*** Available for purchase. Supplied with instrument if ordered as Option 910.Table of Contents1.General InformationWhat’s in this Manual (11)Options (11)Safety Requirements (12)Specifications (12)2.Operation OverviewIntroduction (15)Front Panel Description (16)Remote Programming (16)Local/Remote Control (16)Extended Power Operation (17)Programmable Features (17)Modes of Operation (17)Constant Current CC (Mode) (18)Ranges (18)Immediate Current Level (18)Triggered Current Level (18)Transient Current Level (19)Software Current Limit (19)Slew Rate (19)Constant Resistance (CR) Mode (19)Ranges (20)Immediate Resistance Level (20)Triggered Resistance Level (20)Transient Resistance Level (20)Slew Rate (20)Constant Voltage (CV) Mode (20)Range (20)Immediate Voltage Level (21)Triggered Voltage Level (21)Transient Voltage Level (21)Slew Rate (21)Transient Operation (21)Continuous Transient Operation (22)Pulsed Transient Operation (22)Toggled Transient Operation (23)Triggered Operation (24)Slew Rate and Minimum Transition Time (25)Input Current, Voltage, and Power Measurement (26)Short On/Off (26)Input On/off (27)Saving and Recalling Settings (27)Reading Remote Programming Errors (27)Status Reporting (28)Protection Features (28)Resetting Latched Protection (28)Overvoltage (29)7Overcurrent (29)Overpower (29)Overtemperature (30)Reverse Voltage (30)Control Connector (30)Remote Sensing (30)Monitor Outputs (30)External Programming Input (31)Fault (31)Port On/Off (31)3.InstallationIntroduction (33)Inspection (33)Installing The Modules (33)Procedure (34)Channel Number (35)Installing The Mainframes (35)Cooling (36)Rack Mounting (36)Turn-On Checkout (36)Changing Line Voltage (37)Turn-On/Selftest (38)Power Test (39)Controller Connection (39)GPIB Address (40)Rear Panel Connectors and Switches (40)Input Binding Posts (40)Control Connector (41)Sense Switch (41)Trigger Connector (43)Application Connections (43)Wiring Considerations (43)Local Sense Connections (44)Remote Sense Connections (44)Parallel Connections (44)Zero-Volt Loading Connections (45)4.Local OperationIntroduction (49)Local Control Overview (52)Using The CHAN Keys (53)Selecting the Channel (54)Identifying the Selected Channel (54)Using The Function Keys (54)Turning the Input On/Off (54)Setting the Mode of Operation (56)Setting CC Values (56)Programming Ranges (56)8Examples (56)Setting CR Values (57)Programming Ranges (57)Examples (58)Setting CV Values (59)Programming Range (59)Examples (59)Transient Operation (60)Shorting the Input (61)Resetting Latched Protection (61)Using The System Keys (62)Setting the GPIB Address (62)Displaying Error Codes (62)Saving and Recalling Settings (62)Changing "Wake-up" Settings (63)Recalling the Factory Default Values (63)5.Remote OperationIntroduction (65)Enter/Output Statements (65)GPIB Address (65)Sending A Remote Command (66)Selecting A Channel (66)Getting Data Back (66)Remote Programming Commands (67)CC Mode Example (68)CV Mode Example (68)CR Mode Example (71)Continuous Transient Operation Example (71)Pulsed Transient Operation Example (72)Synchronous Toggled Transient Operation Example (72)6.CalibrationIntroduction (75)Equipment Required (75)Calibration Commands (76)Calibration Flowcharts (77)Example Programs (77)A.Considerations for Operating in Constant Resistance Mode (91)Index (93)Agilent Sales and Support Offices (97)91 General InformationWhat’s In This ManualThis manual applies to both the Agilent6050A and Agilent 6051A Electronic Load mainframes. The two mainframes are functionally identical, but the Agilent 6051A is a half-rack width unit, with only two slots for load modules. Most of the information given in this manual applies to both mainframes. Where differences occur, information specific just to the Agilent 6051A is given in parentheses following information that applies only to the Agilent 6050A, for example: ... a total of 1800(600) watts...This chapter contains specifications that apply to the Agilent 6050A and Agilent 6051A Electronic Load mainframes, as well as information concerning options and safety requirements. The remaining chapters in this manual contain instructions for installing, operating, programming, and calibrating the Electronic Load as followsChapter 2 "Operation Overview":describes all of the Electronic Load’s functions and briefly describes how they can becontrolled locally at the front panel and/or remotely via a GPIB controller.Chapter 3 "Installation":provides instructions for installing load modules in the mainframe, controller andapplication connections, and turn-on checkout procedures.Chapter 4 "Local Operation":describes in detail how to operate the Electronic Load at the front panel.Chapter 5 "Remote Operation":provides an introduction to remote programming.Chapter 6 "Calibration":contains calibration procedures for the Electronic Load and gives sample calibrationprograms. Yearly calibration intervals are recommended.Specifications and other information pertinent to a specific load module are given in the module-specific pages provided with each load module.OptionsUnless one of the following line voltage options is ordered, the unit is shipped from the factory set for 120 Vac, 48-63 Hz ac input power. If Option 100, 220, or 240 is ordered, the unit will be factory set for the appropriate line voltage.For information about changing the line voltage setting, see "Turn-On Checkout" in Chapter 3.100: Input Power, 100 Vac, 48-63 Hz220: Input Power, 220 Vac, 48-63 Hz240: Input Power, 240 Vac, 48-63 HzAdditional options are:800:One rack mount kit for two half-rack units side by side (Agilent 6051A only)*908:One rack mount kit*909: One rack mount kit with handles (Agilent 6050A only)*910:One service manual with extra Operating Manual and Programming Reference Guide*Support rails are required for Options 800, 908, and 909.General Information 11Safety RequirementsThis product is a Safety Class 1 instrument, which means that it is provided with a protective earth ground terminal. This terminal must be connected to an ac source that has a 3-wire ground receptacle. Review the instrument rear panel and this manual for safety markings and instructions before operating the instrument. Refer to the Safety Summary page at the beginning of this manual for a summary of general safety information. Specific safety information is located at appropriate places in this manual.The Electronic Load is designed to comply with the following safety and environmental requirements:• IEC 348-Safety requirements for electronic measuring apparatus.• CSA 22.2 No. 231-Electronic instruments and scientific apparatus for special use and applications.• UL 1244-Electrical and electronic measuring and testing equipment.S pecificationsT able 1-1 lists the specifications and supplemental characteristics for the Agilent 6050A/6051A Electronic Load mainframe. All specifications apply over an operating range of 0 to +55°C for the mainframe. Specifications are guaranteed through the warranty of the product. Supplemental characteristics are type-tested or typical values based on a product sample and, while representative, are not guaranteed for all instruments.T able 1-1. Agilent 6050A/6051A Specifications and Supplemental CharacteristicsS pecifications:A C Input:T hree internal switches permit operation from 100, 120, 220, or 240 Vac lines.A mplitude:-13% to +6% nominal line voltageF requency:48 to 63 HzS upplemental Characteristics:A C Input:F use: The ac input is protected by internal fuses.M aximum VA: 635G PIB Programming Command Processing Time (Time required for a GPIB command processed by the Electronic Load): 70 milliseconds (typical)G PIB Interface Capabilities:S H1, AH1, T6, L4, SR1, RLI, DT1, DC1T rigger Input:V lo = 0.9 V maximum at Ilo = -1 mAV hi = 3.15 V minimum (pull-up resistor on input)T rigger Input:V lo = 0.72 V maximum at Ilo = 1 mAV hi = 4.4 V minimum at Ilo = -20 µA12 General InformationT able 1-1. Agilent 6050A/6051A Specifications and Supplemental Characteristics (continued)W eight:N et (mainframe only):Agilent 6050A, 9.5 kg (21 lb.)Agilent 6051A, 5.5 kg (12 lb.)S hipping:Agilent 6050A, 14 kg (31 lb.)Agilent 6051A, 7.5 kg (17 lb.)D imensions:W idth:Agilent 6050A, 425.5 mm (16.75 in.)Agilent 6051A, 213 mm (8.4 in.)H eight:178 mm (7 in.), add 10 mm (0.4 in.) for removable feetD epth:625 mm (24.6 in.), including input connectors on modulesGeneral Information 132 O peration OverviewI ntroductionT he Agilent 6050A and Agilent 6051A Multiple Input Electronic Load Mainframes are used for design, manufacturing, and evaluation of dc power supplies, batteries, and power components. Other applications include use as a power circuit breaker or crowbar, high-current function or pulse generator, fuel-cell and photovoltaic cell test, and de-energizing superconducting magnets.T he mainframe contains six (two) slots for load modules. Load modules occupy either 1 or 2 slots, depending on the power rating of the module. The mainframe can dissipate up to 300 watts per slot, to a total of 1800 (600) watts for a fully loaded mainframe. An individual module may have either 1 or 2 channels, each of which has its own channel number. Each module contains its own input connectors. The mainframe contains a processor, GPIB connector and interface circuits, trigger circuits, front-panel keypad and display, and other circuits common to all the load modules.E ach module can operate independently in constant current (CC) mode, constant voltage (CV) mode , or constant resistance (CR) mode. In addition, each input can be turned on or off (open circuit) or short circuited.F eatures include built-in GPIB interface and built-in pulse generator, both standard. Pulse mode allows dynamic testing of power supplies and components, without giving the device under test time to heat up. The flexible pulse mode provides six triggering methods, allowing synchronization with a wide variety of events. A Save/Recall feature allows you to save up to 7 complete instrument setups, one of which can be saved in non-volatile memory so that it is recalled automatically at power-on. Also standard is GPIB readback of actual input voltage and current, and extensive protection and status reporting capability.T he mainframe contains two (one) cooling fans whose speed automatically increases or decreases as the module temperatures rise and fall. This feature reduces overall noise level because the fans do not run at maximum speed at all times.T he input power rating curve for each module is shown in the module-specific pages. See the extended power paragraphs in this section for a description of the power rating curves. Note that regardless of a module’s power rating, input current is derated linearly from 2 volts down to 0 volts.E ach load module can be individually controlled either via GPIB or locally via the front panel. Once a channel is selected or addressed, all subsequent commands go to that channel until another channel is selected or addressed. Operation of all models is similar, regardless of power ratings. Therefore, the operating instructions given in this manual are generic, and apply to all modules. The module-specific pages provided with each module include specifications and other information pertinent just to a particular model. Some examples described here may use values that are not appropriate for your module, but the example is valid. Some descriptions refer to ranges, limits, full-scale values, and similar terms (for example, low range and high range). Refer to the module-specific pages provided with each module for the actual values.P rograms written for the Agilent 6060 series of single Electronic Loads can be used with the multiple loads, easing program development for applications using various members of the Agilent Electronic Load family. (Triggering via the ac line frequency or the load’s internal timer is available only in the multiple load mainframe.)I f your application requires a greater power or current capacity than one module can provide, load modules can be connected in parallel in CC or CR mode.O peration Overview 15F ront Panel DescriptionT he front panel includes a 12-character alphanumeric display, 11 status indicators, and four groups of keypads. Ordinarily the alphanumeric display shows the number of the channel presently under front-panel control, and the input voltage and current of that channel. By using thekey. If you change channels via the front panel, any fault information will be displayed first for the new channel. Then you can key through the display in the normal sequence. The alphanumeric display also shows what function is being performed when you use the keypads.T he display also includes 11 annunciators that point to the 11 status labels printed on the front panel. The ConstantC urrent, Constant Resistance, Constant Voltage, Transient, and Unregulated status annunciators are specific to the channel displayed. The Protection, Error, Shift, Remote, Address, and Service ReQuest status annunciators are channel independent.F our of the keys perform two functions, with the alternative function labeled in blue above the key. The alternative function is selected by first pressing the blue (shift) key, which turns on the Shift annunciator and enables the alternative function.N ote that the front-panel display operates independently from the GPIB CHANNEL command. In other words, you can select a channel locally (front panel) for which the display will show the input voltage and current, and the controller can subsequently send commands to other channels without changing the channel being displayed.R emote ProgrammingC ommands sent to the Electronic Load via GPIB are decoded by the mainframe microprocessor, which detects syntax and range errors. The mainframe processor also prescales data sent to the modules, and maintains status registers for each module. Three commands have aliases for compatibility with other HPSL instruments. MODE can also be called FUNCtion, INPut can also be called OUTPut, and CHANnel can also be called INSTrument. OUTPut and INSTrument would typically be used if you want your program to refer to the load modules in terms of the device or instrument under test. Be careful if using INSTrument for CHANnel in systems that have more than one Electronic Load mainframe; someone looking at the listing in the future may be misled.L ocal/Remote ControlL ocal (front panel) control is in effect immediately after power is applied. The front panel keypad and display allow manual control of each individual module when the Electronic Load is used in bench test applications. Remote (computer) control goes into effect (front panel Rmt annunciator is on) as soon as the mainframe receives a command via the GPIB. A built-in GPIB interface and HPSL compatible commands allow control and readback of all functions when the Electronic Load is used in computer controlled applications.W ith remote control in effect, only the computer can control the Electronic Load; the front panel keypad has no effect. You can, however, still use the front panel display to view the input voltage and current readings. You can return the ElectronicLoad to local control from remote control by pressing16 Operation Overview。

content的用法和短语例句【导语】早上记住content的短语，下午熟悉它的用法，晚上就掌握它的例句。

以下是给大家带来content的用法和短语及参考例句，以供参阅。

【篇一】content的用法大全content的用法1：content的基本意思有三:第一,可表示“所容纳之物,所含之物”,指某一物体中所含的具体东西; 第二,表示一本书或文章中所包含的“内容”,可以是具体的内容,也可以是抽象的内容; 第三,表示某一容器的“容量”或某一物质在另一物质中的“含量”。

content的用法2：content表示“内容”时用单数和复数的意思不同,用复数表示具体的内容,而用单数则表示与形式相对应比较抽象的“要旨,内含”; 在表示“含量,容量”时只能用单数; 表示“所容纳之物,所含之物”时多用复数。

content的用法3：content的基本意思是“使满足,使满意”,指做一些让人高兴的事情,以使他人感到满足,其宾语多为人。

content的用法4：content主要用作及物动词,后接名词或代词作宾语。

content的用法5：content常用于content oneself with结构,表示“满足于…”。

content的用法6：content作形容词时意思是“愿意和渴望得到满足的”,这种满足的程度不一定是完全彻底的,但人已不必再为此或为彼而心烦意乱了。

content的用法7：content后可接with引起的短语或动词不定式,表示“能够这样(做)已经知足了”,有时还可接that从句。

content的用法8：content在句中主要用作表语。

content的用法9：content没有比较级和级。

【篇二】content的常用短语用作动词 (v.)content with (v.+prep.)用作名词 (n.)to one’s heart’s content用作形容词 (adj.)content with【篇三】content的用法例句1. There are reports of widespread dis-content in the capital.有报道称首都弥漫着不满的情绪。

table of contents 例子Table of Contents Example:Chapter 1: Introduction1.1 Background1.2 Purpose of the Study1.3 Research Questions1.4 Significance of the StudyChapter 2: Literature Review2.1 Theoretical Framework2.2 Previous Studies2.3 Gaps in the Literature2.4 Conceptual FrameworkChapter 3: Methodology3.1 Research Design3.2 Data Collection Methods3.3 Sampling Technique3.4 Data AnalysisChapter 4: Results4.1 Presentation of Findings4.2 Analysis of Results4.3 Discussion of FindingsChapter 5: Conclusion5.1 Summary of the Study5.2 Implications of the Study5.3 Limitations and Recommendations for Future Research ReferencesAppendices附录A: 调查问卷附录B: 原始数据以上是一个使用中文的目录示例，共包含五个章节，每个章节下分为几个小节进行细分。

章节1介绍研究的背景、目的、研究问题和研究的重要性。

章节2进行文献综述，包括理论框架、先前研究、文献的不足之处以及概念框架。

章节3详细描述了研究的方法论，包括研究设计、数据收集方法、抽样技术和数据分析。

章节4呈现了研究结果，并进行了结果分析和讨论。